Skip to main content

Table 2 Overall outcome of stimulation using a "low dose step-up" protocol and comparison between HP-uFSH and r-FSH (* values are expressed as mean ± SD; ns = not significant)

From: Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-FSH vs. HP-uFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis

 

overall

HP-uFSH

rFSH

P

N. of patients

260

130

130

 

N. of stimulation cycles

260

130

130

 

Total FSH dose (IU) *

733 ± 387

844 ± 305

668 ± 276

.0003

Duration of follicular phase (days) *

12.3 ± 2.5

12.7 ± 2.6

11.7 ± 2.5

ns

No. of preovulatory follicles ≥ 18 mm at hCG *

1.8 ± 1.2

1.9 ± 1.1

1.8 ± 1.2

ns

No. of follicles 12–17 mm at hCG *

3.8 ± 1.6

3.7 ± 1.9

3.8 ± 1.6

ns

Size of the dominant follicle at hCG (mm) *

20.2 ± 1.1

20.1 ± 1.0

20.3 ± 0.9

ns

Endometrial thickness at hCG (mm) *

10.4 ± 1.5

10.8 ± 1.1

9.9 ± 1.8

ns

Monofollicular cycles (%)

178 (68.5)

87 (66.9)

91 (70.0)

ns

Bi-/trifollicular cycles (%)

32 (12.3)

16 (12.3)

16 (12.3)

ns

Cancelled cycles (%)

50 (19.2)

27 (20.8)

23 (17.7)

ns

Deliveries

30

13

17

 

Delivery rate/started cycle (%)

11.5

10.0 (95%CI: 4.5–15.2)

13.1 (95%CI: 7.3–18.9)

ns

Delivery rate/ovulatory cycle (%)

13.6

12.0

15.2

ns